Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


King R&D Inc.

Division of Pfizer Inc.

Latest From King R&D Inc.

Norak Biosciences Inc.

Norak's founders think that beta-arrestin's movement from within the body of the cell to the membrane-bound receptor is a specific marker of GPCR receptor activation-and their method for watching it all happen in glowing green is the basis of the company's Transfluor technology.
BioPharmaceutical Strategy

Opportunism Knocks

In this era of pharmaceutical industry consolidation, large pharmaceutical companies, and in particular the newly-merged, taking stock of their increasing bulk, have been heard to say that they will drop products in development that don't have the potential to achieve at least $500 million in revenues. Big pharmas are also looking more critically at their small products already on the market. For these large companies, small products could prove to be a distraction that diverts resources away from potential blockbusters, the kinds of products that the companies will need to grow by 15% a year going forward. In theory, then, as pharmaceutical companies up-average product portfolios in favor of high-revenue producers and prune away redundant or non-strategic products in the aftermath of mergers, many more commercializable products should become available for licensing than ever before. That is the hope, anyway, of a handful of new specialty pharmaceutical companies formed to acquire on-the-market products with the aim of growing their sales through a variety of strategies. These companies avoid product development risk but bear risk of a different sort. To be successful, they must be able to continually acquire products that can grow, and not pay too much for them.
BioPharmaceutical Strategy

Drugs for Congestive Heart Failure

A drug maker with a new CHF treatment will be helping to fill a serious unmet clinical need and benefiting from a huge, chronic care market. But development costs are huge and risks are high: the clinical history is lined with failed drugs. Thus, most CHF drug projects are in large companies; biotechs cluster at the pre-compound discovery end.

Molecular Targeting Technology Inc.

Molecular Targeting Technology is developing radiopharmaceuticals for nuclear medicine and targeting agents for drug delivery. The company's lead product, {Amiscan} uses a small-molecule radiotracer to diagnose heart attack.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Medco Research Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Pfizer Inc.
  • Senior Management
  • Terry E Willard, VP, Mktg.& Bus. Dev.
    Nils Johannesson, MD, PhD, VP, R&D
  • Contact Info
  • King R&D Inc.
    Phone: (919) 653-7001
    7001 Weston Parkway Suite 300
    Cary, NC 27513